Degranulation of Mast Cells as a Target for Drug Development

Cells. 2023 May 29;12(11):1506. doi: 10.3390/cells12111506.

Abstract

Mast cells act as key effector cells of inflammatory responses through degranulation. Mast cell degranulation is induced by the activation of cell surface receptors, such as FcεRI, MRGPRX2/B2, and P2RX7. Each receptor, except FcεRI, varies in its expression pattern depending on the tissue, which contributes to their differing involvement in inflammatory responses depending on the site of occurrence. Focusing on the mechanism of allergic inflammatory responses by mast cells, this review will describe newly identified mast cell receptors in terms of their involvement in degranulation induction and patterns of tissue-specific expression. In addition, new drugs targeting mast cell degranulation for the treatment of allergy-related diseases will be introduced.

Keywords: IgE-targeted drugs; degranulation; mast cells.

Publication types

  • Review

MeSH terms

  • Drug Development
  • Humans
  • Hypersensitivity* / metabolism
  • Mast Cells* / metabolism
  • Nerve Tissue Proteins / metabolism
  • Receptors, G-Protein-Coupled / metabolism
  • Receptors, IgE / metabolism
  • Receptors, Neuropeptide / metabolism

Substances

  • Receptors, IgE
  • MRGPRX2 protein, human
  • Nerve Tissue Proteins
  • Receptors, Neuropeptide
  • Receptors, G-Protein-Coupled

Grants and funding

This research received no external funding.